Dr Juan José Serrano

• Melanoma
• Other skin tumours, including basal cell carcinoma, squamous cell carcinoma and Merkel cell carcinoma.
• Genetic counselling and familial cancer risk assessment.

Academic Training

• Degree in Medicine from Universidad Complutense de Madrid, 2014.
• Specialist in Medical Oncology via the Spanish MIR system at Hospital Universitario Ramón y Cajal, 2015–2020.
• University-specific Master’s Degree in Integration and Resolution of Clinical Problems in Medicine, Universidad de Alcalá, 2015.
• University-specific Master’s Degree in Medical Oncology: SEOM Certification, Universitat de Girona, 2019.
• ESMO Examination Certificate, 2019 and 2021.
• IX Edition of the Hereditary Cancer Course: SEOM Certification, 2020.
• University-specific Expert Diploma in Tumour Immunology and Cancer Immunotherapy, Universidad de Alcalá, 2023.
• University-specific Master’s Degree in Design and Analysis of Health Sciences Research, Universitat Autònoma de Barcelona, 2024.

Professional Career

• Hospital Universitario Ramón y Cajal — gastrointestinal tumours, sarcomas, brain tumours and genetic counselling, 2020–2021.
• Hospital Universitario Rey Juan Carlos — gastrointestinal tumours, melanoma and genetic counselling, 2021.
• Hospital Universitario Ramón y Cajal — melanoma and other skin tumours, and head and neck tumours, 2021–2023.
• Hospital Vithas La Milagrosa — genitourinary tumours, melanoma and other skin tumours, and genetic counselling.

• Member of the Grupo Español Multidisciplinar de Melanoma (GEM).
• Member of the Sociedad Española de Oncología Médica (SEOM).
• Member of the European Society for Medical Oncology (ESMO).
• Author of more than 15 scientific articles, including:
  • Anthracyclines-induced cardiotoxicity in patients with early breast cancer carrying germline BRCA1/2 mutation: the BRCAN study. Oncologist. 2025 Aug 4;30(8):oyae299. doi: 10.1093/oncolo/oyae299.
  • Real-life evidence of encorafenib plus binimetinib in patients with unresectable advanced or metastatic BRAFV600-mutant melanoma in Spain: the BECARE (GEM-2002) trial. Front Oncol. 2025 Feb 26;15:1466185. doi: 10.3389/fonc.2025.1466185.
  • Efficacy and safety of cemiplimab in the treatment of advanced cutaneous squamous cell carcinoma: A multicentre real-world retrospective study from Spain and systematic review of the published data. J Eur Acad Dermatol Venereol. 2024 Aug;38(8):e666-e670. doi: 10.1111/jdv.19821.
  • Extramammary Paget Disease: a Therapeutic Challenge, for a Rare Entity. Curr Oncol Rep. 2023 Oct;25(10):1081-1094. doi: 10.1007/s11912-023-01434-0.
  • Negative association of steroids with immunotherapy efficacy in a multi-tumor cohort: time and dose-dependent. Cancer Immunol Immunother. 2024 Aug 2;73(10):186. doi: 10.1007/s00262-024-03772-9.
  • Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments. Eur J Cancer. 2022 May;166:229-239. doi: 10.1016/j.ejca.2022.02.017.
• Autor de varios capítulos de libro y de más de 45 comunicaciones a congresos internacionales y 30 a congresos nacionales